TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21755811
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (dorzolamide 20 mg/ml + timolol 5 mg/ml eye drops)
Study: 16430342
Drug: Duloxetine 60
Normalized name: duloxetine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 60 mg BID and Routine care
Study: 6311392
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy with cyclophosphamide (1.5 g/m2 days 1‐3), 4‐dimethyl epipodophylloxtin (200 mg/m2 days 1‐3), vincristine (1.5 mg/m2 days 1 and 3), and Adriamycin (80 mg/m2 day 1)
Study: 6311392
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy without Adriamycin
Study: 6311392
Drug: Prophylactic brain
Normalized name: pork brain preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic brain irradiation (3000 rad) and 4 courses of usual doses of the same drugs
Study: 28498636
Drug: Preoperative bowel
Normalized name: ascorbic acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative bowel stimulation via the distal limb of the loop ileostomy using an 18Fr Foley catheter and infusing with 500 ml of normal saline mixed with 30 g of a thickening agent (Nestle© Thicken‐Up©), performed 10 times over 3 weeks before ileostomy closure.
Study: 21252171
Drug: Prasugrel 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel 60 mg loading dose (LD)/10 mg maintenance dose (MD)
Study: 21252171
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg LD/150 mg MD
Study: 25653574
Drug: Fondaparinux 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fondaparinux 1.5 mg once daily
Study: 23819225
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of western medicine
Study: 11558009
Drug: Intercostal Nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal Nerve Block (ICB) with Bupivacaine (BUP) 3 mg/kg 0.5 % with epinephrine 1 : 200 000
Study: 11558009
Drug: Meperidine 1
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 1 mg/kg administered i.v.
Study: 9626638
Drug: PTH (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH (400 IU/day subcutaneous human PTH (1-34)) + alendronate (10 mg/day)
Study: 9626638
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/day) alone
Study: 2646848
Drug: Intravenous bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous bupivacaine 0.5% 20 ml with adrenaline (5 micrograms/ml) administered through an indwelling intrapleural catheter at 4-hour intervals four times daily for 2 days.
Study: 2646848
Drug: Intramuscular oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular oxycodone on request (control group).
Study: 1101615
Drug: etidocaine 1%
Normalized name: etidocaine 1% preservative-free injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: etidocaine 1% with adrenaline 5 mug/ml
Study: 1108582
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% with adrenaline 5 mug/ml
Study: 10773182
Drug: Antidepressant agents
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant agents
Study: 9483814
Drug: Paracervical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracervical anaesthesia (2 x 10 ml 0.5% Bupivacain solution)
Study: 8416441
Drug: Zoladex (goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex (goserelin 3.6 mg) implant every 4 weeks plus estradiol valerate, 2 mg/day, with norethisterone 5 mg from days 22-28
Study: 8416441
Drug: Zoladex (goserelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zoladex (goserelin 3.6 mg) implant every 4 weeks plus placebo ERT tablets daily
Study: 8416441
Drug: Placebo implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo implant every 4 weeks plus placebo ERT tablets daily
Study: 3792432
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 10 mg ketanserin
Study: 3792432
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 10 mg ketanserin
Study: 3792432
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 20 mg ketanserin
Study: 3792432
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 40 mg ketanserin
Study: 3792432
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 60 mg ketanserin
Study: 18782439
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg sCT with 50 ml of water
Study: 18782439
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg sCT with 50 ml of water taken 30 and 60 minutes prior to meal time
Study: 15940460
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg erythromycin
Study: 15940460
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg erythromycin
Study: 10071275
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg, 2-hour intravenous infusion every 4 weeks for 24 cycles)
Study: 10071275
Drug: Placebo (2-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2-hour intravenous infusion every 4 weeks for 24 cycles)
Study: 7564371
Drug: Diltiazem CD
Normalized name: Diltiazem Hydrochloride 300 MG Oral Capsule, Extended Release, 24 HR [DILTIAZEM CD]
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem CD (once-daily controlled-delivery)
Study: 7564371
Drug: Diltiazem SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem SR (twice-daily sustained-release)
Study: 28540844
Drug: Fp MDPI
Normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp MDPI 200 μg
Study: 28540844
Drug: FS MDPI
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS MDPI 200/12.5 μg
Study: 28540844
Drug: Fp HFA
Normalized name: FP-1096
DrugBank: FP-1096 (DB05310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fp HFA 440 μg
Study: 28540844
Drug: FS DPI
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: FS DPI 500/50 μg
Study: 28540844
Drug: All Fp
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All Fp MDPI doses
Study: 28540844
Drug: All FS
Normalized name: Derma-Smoothe FS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All FS MDPI doses
Study: 25839338
Drug: Shakuyaku-Kanzo-to (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shakuyaku-Kanzo-to (7.5 g/d)
Study: 25839338
Drug: Biperiden (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biperiden (3 mg/d)
Study: 24004620
Drug: Prolonged use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged use of aspirin before tooth extraction (observation group I)
Study: 24004620
Drug: Prolonged use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged use of aspirin before tooth extraction (observation group II)
Study: 24004620
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin before tooth extraction (control group I)
Study: 24004620
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin before tooth extraction (control group II)
Study: 5082545
Drug: Metolazone (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metolazone (doses ranging from 20-150 mg)
Study: 23469947
Drug: Plasma g-tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma g-tocopherol
Study: 21510895
Drug: Methylphenidate (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.5 mg/kg in divided b.i.d. dose)
Study: 6389142
Drug: Chronic antidysrhythmic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic antidysrhythmic treatment (specific agents not mentioned)
Study: 6389142
Drug: Control (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (not specified, but implied to be no treatment or placebo)
Study: 6389142
Drug: Chronic antidysrhythmic
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic antidysrhythmic treatment
Study: 26597179
Drug: Edoxaban 60
Normalized name: edoxaban 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban 60 mg daily for 3 days
Study: 26597179
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from Rivaroxaban 20 mg daily to Edoxaban 60 mg
Study: 26597179
Drug: Switching from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switching from Dabigatran Etexilate 150 mg twice daily to Edoxaban 60 mg
Study: 27536427
Drug: MLK 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLK 10mg (7-day administration)
Study: 27536427
Drug: MLK 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLK 10mg (3-day administration)
Study: 27536427
Drug: MLK 10mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLK 10mg (1-day administration)
Study: 12925048
Drug: Hydrochlorothiazide (HCTZ)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCTZ) 12.5 mg od
Study: 12925048
Drug: Indapamide 2.5
Normalized name: indapamide 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide 2.5 mg od
Study: 10843301
Drug: Alcohol (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (dose sufficient to raise blood alcohol level to .08)
Study: 8076052
Drug: Conventional non-operative
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional non-operative treatment
Study: 3987178
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg every 6 hours by mouth)
Study: 3987178
Drug: Ranitidine (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (160 mg every 12 hours by mouth)
Study: 24712335
Drug: Telephonic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephonic medication therapy management (MTM) intervention
Study: 25614280
Drug: Mipomersen 200
Normalized name: mipomersen 200 mg/mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mipomersen 200 mg weekly subcutaneous
Study: 19127911
Drug: General regulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: General regulation acupuncture and cupping therapy (warming needle moxibustion, plum-blossom needle, moving cupping, retaining the cup), thrice each week for 3 months
Study: 12808177
Drug: Daytime dwell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daytime dwell with 1100 ml/m2 icodextrin solution for one week (week 2)
Study: 10584283
Drug: Preseasonal short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preseasonal short-term immunotherapy
Study: 8738859
Drug: Magnesium infusion
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium infusion (8.12 mmol/day, group A, n = 81)
Study: 8738859
Drug: Potassium infusion
Normalized name: Potassium
DrugBank: Potassium (DB14500)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium infusion (10.49 mmol/day, group B, n = 77)
Study: 8738859
Drug: 10% dextrose
Normalized name: Aminosyn II 4.25% in 10% Dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% dextrose solution (group C, n = 87)
Study: 8738859
Drug: Placebo (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2% dextrose solution, group D, n = 81)
Study: 6339293
Drug: Halometasone/triclosan cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halometasone/triclosan cream
Study: 6339293
Drug: Nerisona C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerisona C cream
Study: 24549596
Drug: Metformin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin treatment (1,000 mg/day)
Study: 21049734
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation containing kojic acid, emblica extract, and glycolic acid
Study: 18201437
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg daily)
Study: 10200006
Drug: Loratadine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loratadine (10 mg daily)
Study: 12037372
Drug: Elmex toothpaste
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elmex toothpaste for unsupervised home use daily and Elmex gel for use once a week
Study: 12037372
Drug: Elmex toothpaste
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elmex toothpaste and placebo gel
Study: 12037372
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (usual oral care habits)
Study: 7897151
Drug: Hydroxyzine 25
Normalized name: hydroxyzine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 25 mg with cimetidine 600 mg every 12 hours for 10 days
Study: 7897151
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg with cimetidine 600 mg every 12 hours for 10 days
Study: 2650604
Drug: Rectal endosonography
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal endosonography (ES)
Study: 23843020
Drug: Conference calls
Normalized name: miconazole nitrate Topical Cream [Clearly Confident]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conference calls (CC)
Study: 17699310
Drug: Omacor 4-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor 4-g dosage
Study: 17699310
Drug: Omacor 8-g
Normalized name: patiromer
DrugBank: Patiromer (DB09263)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omacor 8-g dosage
Study: 26804646
Drug: JNJ‐40411813 (50mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐40411813 (50mg to 150 mg b.i.d, flexibly dosed)
Study: 24521953
Drug: Weight-based dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight-based dosing (20 mg/kg)
Study: 24521953
Drug: Standard dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dosing (1 g)
Study: 22172554
Drug: Choline supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline supplementation (1 g per day as choline bitartrate)
Study: 15780099
Drug: Sirolimus combined
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus combined with low-dose calcineurin inhibitors
Study: 18054611
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (MgSO4) therapy
Study: 9687101
Drug: Amoxycillin (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (5, 7.5, or 10 mg/kg)
Study: 9687101
Drug: Amoxycillin (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (any dose)
Study: 9687101
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (2.5, 5, 7.5, or 10 mg/kg)
Study: 9687101
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (2.5, 5, 7.5, or 10 mg/kg)
Study: 9687101
Drug: Amoxycillin (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin (oral doses)
Study: 9687101
Drug: Cefpodoxime proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime proxetil (oral doses)
Study: 9687101
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil (oral doses)
Study: 22383630
Drug: Oral pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pioglitazone (PIO) 15 mg once daily for 12 weeks
Study: 15030738
Drug: Docetaxel in
Normalized name: docetaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel in combination with cisplatin (DP)
Study: 12171669
Drug: Initial syphilis
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial syphilis screening using rapid plasma reagin or Venereal Disease Research Laboratory tests, confirmed by fluorescent treponemal antibody absorption.
Study: 2815968
Drug: Suckling mouse
Normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suckling mouse brain rabies vaccine with equine hyperimmune serum (40 IU per kg body weight)
Study: 2815968
Drug: Suckling mouse
Normalized name: house mouse skin extract
DrugBank: Mus musculus skin (DB10412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suckling mouse brain rabies vaccine without equine hyperimmune serum
Study: 25939894
Drug: Cilengitide 2000
Normalized name: Cilengitide
DrugBank: Cilengitide (DB11890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilengitide 2000 mg 1×/week i.v. (CIL-once)
Study: 25939894
Drug: Control (cetuximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (cetuximab plus platinum-based chemotherapy)
Study: 18593517
Drug: Valsartan/HCTZ (160/12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan/HCTZ (160/12.5 mg, titrated to 160/25 mg after 2 weeks and to 320/25 mg after 4 weeks)
Study: 18593517
Drug: Valsartan monotherapy
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan monotherapy (160 mg, titrated to 320 mg after 2 weeks and sham-titrated to 320 mg after 4 weeks)
Study: 16295261
Drug: Participation in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participation in research aimed at determining treatment effectiveness
Study: 16295261
Drug: Established treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Established treatments
Study: 12232450
Drug: Noncorticosteroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noncorticosteroid treatment (control group)
Study: 10406361
Drug: Behavioural intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioural intervention by an old-age psychiatry hospital outreach team, including seminars and weekly visits from a psychiatric nurse over 6 months.
Study: 1979494
Drug: Drug A
Normalized name: Drug additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug A (propyphenazone 250 mg, ethylmorphine 5 mg, caffeine 5 mg)
Study: 1979494
Drug: Drug B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug B (dipyrone 500 mg, diphenhydramine 12.5 mg, adiphenine 5 mg, ethyl aminobenzoate 2.5 mg)
Study: 375943
Drug: 1-phenylephrine hydrochloride
Normalized name: chlorpheniramine
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-phenylephrine hydrochloride gel
Study: 15757015
Drug: Alendronate 5
Normalized name: ALENDRONATE 5MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 5 mg/d for 2 years and 10 mg/d thereafter
Study: 12618160
Drug: Continuous combined
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous combined hormone replacement therapy (2 mg 17beta‐oestradiol and 1 mg norethisterone acetate)
Study: 9350383
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral zolmitriptan
Study: 9350383
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oral ergotamine
Study: 9350383
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of zolmitriptan and ergotamine
Study: 29717288
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 5 mg
Study: 29717288
Drug: Hyperbaric bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric bupivacaine 5 mg plus dexmedetomidine 5 µg intrathecally
Study: 18514303
Drug: gemcitabine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine plus axitinib (1000 mg/m² plus 5 mg twice daily)
Study: 18514303
Drug: gemcitabine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine alone (1000 mg/m²)
Study: 11800503
Drug: Amisulpride 50
Normalized name: amisulpride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amisulpride 50 mg o.d.
Study: 11800503
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg o.d.
Study: 8645650
Drug: Goserelin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin treatment in women with adenomyosis
Study: 31648967
Drug: DWI+FLAIR sequences
Approvals — FDA: no, EMA: no, PMDA: no
Description: DWI+FLAIR sequences in combination
Study: 27622611
Drug: Desmopressin 0.2
Normalized name: DESMOPRESSIN 0.2MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.2 mg
Study: 11696804
Drug: Desmopressin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.4 mg
Study: 11696804
Drug: Desmopressin 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmopressin 0.6 mg
Study: 7953039
Drug: Family-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based intervention including monthly 45-minute counselling sessions focused on management of social and occupational problems, medication management, family education, family group meetings, and crisis intervention.
Study: 3069568
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g i.v. Cefotetan
Study: 27032449
Drug: Internet-based problem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based problem solving therapy with weekly student support (n=136)
Study: 27032449
Drug: Internet-based problem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based problem solving therapy (n=136)
Study: 24173623
Drug: Sertraline 50
Normalized name: sertraline 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline 50 mg to a maximum of 200 mg/day
Study: 24173623
Drug: Sertraline (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (in subset meeting DSM-IV criteria)
Study: 23690416
Drug: Experimental arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Experimental arm (chemotherapy based on ERCC1 and RRM1 levels)
Study: 20569705
Drug: Carperitide treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carperitide treatment (69.4%)